Delivery Order SPE2DB24D2013-SPE2DB25FCKBJ
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $3,425.95 delivery order on August 13, 2025, for 270 tablets of Esbriet 267 mg, a pulmonary fibrosis medication. This competitively awarded, firm fixed-price contract contains no set-aside designation and is scheduled for completion by September 4, 2025. The pharmaceutical supply will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child...
- The Defense Logistics Agency awarded a $17,129.75 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg, a pharmaceutical treatment primarily used for idiopathic pulmonary fibrosis. This firm fixed-price delivery order, which was competitively awarded without set-aside provisions, is scheduled for completion by September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, leveraging the company's...
- The Defense Logistics Agency awarded a delivery order valued at $3,425.95 to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used in the treatment of idiopathic pulmonary fibrosis. This firm fixed-price delivery order, issued on August 18, 2025, with an ultimate completion date of September 9, 2025, carries no set-aside designation and was competitively awarded. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg on August 28, 2025, with completion targeted by September 19, 2025. This competitively awarded, firm fixed-price contract was issued without set-aside provisions and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Esbriet 801 mg tablets (90-count units) on August 18, 2025, with completion targeted for September 9, 2025. This non-set-aside competitive award is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used to treat idiopathic pulmonary fibrosis. The contract, awarded on July 21, 2025, with an ultimate completion date of August 11, 2025, was competitively awarded without set-aside provisions. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,425.95 for 90 tablets of ESBRIET 801 MG, a pharmaceutical product used in the treatment of idiopathic pulmonary fibrosis. This competitively awarded, firm fixed-price delivery order was issued on August 18, 2025, with an ultimate completion date of September 9, 2025. The contract carries no set-aside designation, indicating it was competed among eligible vendors meeting federal procurement standards....
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg on July 30, 2025, with an ultimate completion date of August 20, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet (pirfenidone) 267 mg, with an ultimate completion date of September 22, 2025. This non-set-aside, competitively awarded contract is a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a potential value of $999,999,999 through December 2026. The product will be...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for Esbriet (pirfenidone) 801 mg tablets in a quantity of 90 units. This award, issued on July 21, 2025, with an ultimate completion date of August 11, 2025, represents a non-competitive delivery order under AmerisourceBergen's existing federal contract vehicle. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania,...
- SPE2DB24D2013Indefinite Delivery Contract
- SPE2DB24D2013-SPE2DB25FCKBJDelivery Order
The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg, a pulmonary fibrosis medication. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The pharmaceutical will be delivered to the contractor's location in Conshohocken, Pennsylvania, with an ultimate completion date of September 23, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement supporting military and veteran healthcare systems. Through its comprehensive IDC vehicle, the company supplies a broad range of pharmaceutical products and medical supplies across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide. This specific delivery order demonstrates the company's ongoing role in fulfilling pharmaceutical needs within the DLA's medical supply chain, with no set-aside designation applied to this award.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 9/2/25 |